Shenzhen Hybio Pharmaceutical: difference between revisions
Diff·revision 8 → 9·11:18, 24 Sep 2025
Difference between revision 8 and revision 9 of Shenzhen Hybio Pharmaceutical. 18 lines changed; the page grew by 2,345 bytes.
| Revision 8 — 17:40, 16 Sep 2025 SyringeSybille (talk) rm the comparison with another supplier; there is no common basis for it 4,764 bytes +33 | Revision 9 — 11:18, 24 Sep 2025 Chromatokid (talk) add the storage and handling guidance the organisation publishes 7,109 bytes +2,345 | ||
|---|---|---|---|
| 1 | {{Infobox organisation | 1 | {{Infobox organisation |
| 2 | | name = Shenzhen Hybio Pharmaceutical Co., Ltd. | 2 | | name = Shenzhen Hybio Pharmaceutical Co., Ltd. |
| + | 3 | | image = facility.svg | |
| + | 4 | | caption = Schematic synthesis and quality-control site. No image of this organisation's premises is available to this wiki. | |
| 3 | | Legal name = Shenzhen Hybio Pharmaceutical Co., Ltd. | 5 | | Legal name = Shenzhen Hybio Pharmaceutical Co., Ltd. |
| 4 | | Trading name = HYB | 6 | | Trading name = HYB |
| ⋮ | ⋮ | ||
| 27 | The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report. | 29 | The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report. |
| 28 | 30 | ||
| + | 31 | == Operations and documentation practice == | |
| + | 32 | Purchaser reports describe vialled lyophilised material arriving with a batch-specific [[Certificate of analysis|certificate]] naming a [[Batch number|lot]], and across the submitted set the lot string on the certificate has corresponded to the vial label.{{r|reports}} That correspondence is a minimum requirement rather than an achievement, and it is recorded only because [[Lot traceability|traceability]] fails often enough elsewhere in this sector to make its absence the more common finding. | |
| + | 33 | ||
| + | 34 | Water content by [[Karl Fischer titration|Karl Fischer titration]] appears on the certificates described in the submitted set more often than for most entities covered here, and [[Peptide content|peptide content]] is reported on a separate line from chromatographic purity across a substantial part of it.{{r|reports,usp1503}} Those two determinations are what let a purity percentage be read as a statement about mass, and their routine presence is the most useful documentary observation available about this organisation. | |
| + | 35 | ||
| + | 36 | == Product range == | |
| + | 37 | | Class | Representative listings | Documentation reported | | |
| + | 38 | |---|---|---| | |
| + | 39 | | Peptide active ingredients | Bulk peptide actives, protected fragments | Specification sheet with purity, water and content | | |
| + | 40 | | Incretin analogues | Semaglutide, tirzepatide, retatrutide | Batch certificate with HPLC trace and mass confirmation | | |
| + | 41 | | Research peptides | BPC-157, TB-500, growth-hormone secretagogues | Certificate with purity, appearance and water | | |
| + | 42 | | Custom synthesis | Sequences quoted individually | Certificate with mass confirmation and stated analytical conditions | | |
| + | 43 | | Raw materials | Bulk powders | Certificate with purity; specification sheet on request | | |
| + | 44 | ||
| 29 | == References == | 45 | == References == |
| 30 | {{reflist}} | 46 | {{reflist}} |
| 31 | <ref name="registry">National Enterprise Credit Information Publicity System (国家企业信用信息公示系统), company registration record, retrieved 2026. Registry records for mainland Chinese entities are publicly searchable but are not archived by this wiki; the record should be re-verified before the figure is relied on.</ref> | 47 | <ref name="registry">National Enterprise Credit Information Publicity System (国家企业信用信息公示系统), company registration record, retrieved 2026. Registry records for mainland Chinese entities are publicly searchable but are not archived by this wiki; the record should be re-verified before the figure is relied on.</ref> |
| 32 | <ref name="selfpub">Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per [[Project:Verifiability]].</ref> | 48 | <ref name="selfpub">Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per [[Project:Verifiability]].</ref> |
| + | 49 | <ref name="reports">Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See [[Blind sampling]].</ref> | |
| 33 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> | 50 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> |
| + | 51 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | |
| 34 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 52 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| 35 | 53 |